<DOC>
	<DOCNO>NCT01188707</DOCNO>
	<brief_summary>The Belinostat-Erlotinib trial design open , non randomize phase I / II trial ass efficacy safety Belinostat combination Erlotinib patient non-small cell lung cancer eligible treatment erlotinib .</brief_summary>
	<brief_title>A Trial Belinostat Combination With Erlotinib Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description>Belinostat , develop CuraGen , belong new class hydroxymat-type histone deacetylase ( HDAC ) inhibitor . HDAC inhibitor , include Belinostat , show marked vitro vivo activity number solid tumor hematological cancer . Belinostat proven effective single agent combination anticancer agent doxorubcin , paclitaxel , carboplatin , fluorouracil , bortezumib , observe synergy Belinostat HDAC inhibitor EGFR inhibitor gefinitinib erlonitib . Furthermore , antineoplastic activity Belinostat see preclinical experiment result moderate toxicity . In two Phase I trials Belinostat solid tumor hematological malignancy Belinostat well tolerate dos 2000 mg daily 100 patient . Fatigue , nausea vomit main side effect none mild hematologic toxicity . Approximately 25 % patient study solid tumor achieve stable disease .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Belinostat</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Signed consent approve informed consent form 2 . A . For dose escalation phase : Patients histological cytological confirm nonsmall cell lung cancer rat suitable treatment Erlotinib B . For MTD expansion phase : Patients diagnose non small cell lung cancer rat suitable treatment Erlotinib measurable disease accord RECIST version 1.1 3 . Performance status ( ECOG ) ≤ 2 4 . Life expectancy least 3 month 5 . Age ≥ 18 year 6 . Acceptable liver , kidney bone marrow function , define : Bilirubin ≤ 1.5 x upper limit normal ( ULN ) ASAT , ALAT alkaline phosphatase ≤ 3 x ULN ( liver metastasis ≤ 5 x ULN allow ) Serum creatinine ≤ 1.5 x upper limit normal ( ULN ) WBC &gt; 2.5 x 109 / l , neutrophils &gt; 1.0 x 109 / l , platelet &gt; 100 x 109 / l Hemoglobin &gt; 9.0 g / dl &gt; 5.6 mmol / l 7 . Acceptable coagulation : PT APTT within ≤ 1.5 x ULN therapeutic range give anticoagulant 8 . A negative pregnancy test woman childbearing age . In fertile men woman use effective contraception method require trial 9 . Serum potassium within normal range 1 . Treatment experimental drug within last 4 week 2 . Former anticancer therapy within last 3 week start experimental treatment , include chemotherapy , radiotherapy , endocrine therapy immunotherapy 3 . Simultaneous presence active infection concomitant present medical condition likely affect experimental procedure , include significant cardiovascular disease ( New York Heart Association Class III IV heart disease , myocardial infarction within past 6 month , unstable angina , congestive heart failure require treatment , unstable arrhythmia need antiarrhythmic drug sign ischemia ECG , mark baseline prolongation QT / QTc interval , example repeat demonstration QTc interval &gt; 500 msec ; long QT syndrome ; require use concurrent medication dosage belinostat day , may cause torsades de pointes ( see Appendix 1 ) . 4 . Altered mental status prevents understand informed consent process / execution necessary experiment 5 . Secondary malignancy present ( previous malignancy accept cured treatment &gt; 3 year ago ) 6 . Intestinal obstruction threaten bowel obstruction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Non small cell lung cancer</keyword>
	<keyword>Belinostat</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>HDAC inhibitor</keyword>
	<keyword>Phase I/II</keyword>
</DOC>